AVBP

AI Memo

ArriVent BioPharma

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Development decision after FURVENT missed its primary endpoint • 2026-12-31

Base target: $17 / p=40% prob

Biggest risk

The failed pivotal primary endpoint materially weakens the former lead thesis. A regulatory path for that FURVENT indication is uncertain, and the ADC programs are too early to establish replacement value. ArriVent has not yet announced its decision on firmonertinib's development path. [#PR-2026-10-06]

Invalidation

Break below $9 or thesis failure.

What would change my mind?

The FURVENT miss may already be substantially reflected in the share price, while the separately studied ALPACCA program and two clinical-stage ADCs preserve potential value. FURVENT showed some favorable secondary-endpoint signals, but these do not reverse the primary-endpoint failure. [#PR-2026-10-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

$17

p=40%

Bull target

$26

p=20%

Bear target

p=40%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ARR-217 initial Phase 1 data
ARR-002 early clinical progress
The FURVENT miss may already be substantially reflected in the share price, while the separately studied ALPACCA program and two clinical-stage ADCs preserve potential value.

BearKey bullets

ARR-217 and ARR-002 remain early-stage programs with unproven clinical efficacy and potential safety or execution setbacks.
[#SEC-8K-2026-08-12] [#8-K-2026-10-13]
FURVENT missed its prespecified primary endpoint; favorable secondary measures do not establish pivotal success.

WatchKey bullets

Development decision after FURVENT missed its primary endpoint

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $17 (p=40%)

Target spread vs base: +53% / -47%

Scenario probabilities

Bull Target: $26 (p=20%)Base Target: $17 (p=40%)Bear Target: $9 (p=40%)

Commentary

The packet's recent coverage reports a sharp selloff following the October 6 trial result; the supplied headlines describe a drop exceeding 48%, but a verified event-day close-to-close return is unavailable. The October 16 anchor is $16.66. The deterministic prior is neutral with a substantial thesis-change score, consistent with a materially changed but partly repriced setup. No reliable post-result analyst target revisions, options skew, short interest, or social-sentiment measure was supplied; zeros in those sentiment fields mean unavailable, not neutral readings. [#PR-2026-10-06]

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ARR-217 initial Phase 1 data
ARR-002 early clinical progress

Scenarios

Bull Target (Scenario probability)

$26 / p=20% prob

Base Target (Scenario probability)

$17 / p=40% prob

Bear Target (Scenario probability)

$9 / p=40% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.80

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Development decision after FURVENT missed its primary endpoint
FURVENT did not meet its primary endpoint of progression-free survival by blinded independent central review: at 240 mg, median PFS was 11.0 months versus 9.5 months for control (p=0.0654). ArriVent is evaluating the full dataset before deciding firmonertinib's development path. Any decision or additional analysis could reset expectations, but the company has not announced a decision date. [#PR-2026-10-06] Company release
Prob 70.00% • Move -12.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ARR-217 initial Phase 1 data
2027-06-30
ArriVent advanced its CDH17-targeted ADC, ARR-217, into Phase 1b dose optimization and said it plans to present initial Phase 1 dose-escalation data at a future medical conference. No presentation date or clinical efficacy result has been confirmed; the date here is an analytical monitoring estimate. [#SEC-8K-2026-08-12]
Prob 55% • Move 12% • Priced-in 20%
ARR-002 early clinical progress
2027-12-31
ArriVent reported dosing the first U.S. patient in the ARR-002 Phase 1 trial for ovarian and endometrial cancer on October 12. Safety, dosing, and early efficacy evidence remain to be established; the monitoring date is an estimate, not company guidance. [#8-K-2026-10-13] Company release
Prob 60% • Move 8% • Priced-in 15%

Risks

ARR-217 and ARR-002 remain early-stage programs with unproven clinical efficacy and potential safety or execution setbacks. [#SEC-8K-2026-08-12] [#8-K-2026-10-13]
FURVENT missed its prespecified primary endpoint; favorable secondary measures do not establish pivotal success. [#PR-2026-10-06]
The June 30 cash-runway projection predates the FURVENT result; future spending, trial continuation, or financing needs may differ. [#SEC-8K-2026-08-12]
The development and regulatory path for firmonertinib in EGFR exon 20 insertion NSCLC remains undecided. [#PR-2026-10-06]

Peers

Symbol	Summary
CGEM	A similar-market-cap clinical oncology biotech candidate from the packet. Its usefulness is limited to financing and sector-risk comparisons; no direct drug-program comparability is established.
ORIC	A targeted-oncology development comparator identified in the prior primary-source review of ArriVent's 10-K, but not a substitute for a program-level valuation comparison. [#10-K-2026-03-05]

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

CGEM

A similar-market-cap clinical oncology biotech candidate from the packet. Its usefulness is limited to financing and sector-risk comparisons; no direct drug-program comparability is established.

ORIC

A targeted-oncology development comparator identified in the prior primary-source review of ArriVent's 10-K, but not a substitute for a program-level valuation comparison. [#10-K-2026-03-05]